NPS Pharmaceuticals reiterated at buy by Jefferies

NPS Pharmaceuticals, Inc. was reiterated at buy by Jefferies & Co., Inc. analysts Adam A. Walsh and Salveen Kochnover based on news the company's Phase II trial of teduglutide for short bowel syndrome showed the drug to be well-tolerated. The company is now initiating its Phase III trial, which is over 50% subscribed. NPS shares closed Friday down $0.30, or 3.14%, at $9.24 on volume of 627,298 shares compared to a three-month trailing volume of 436,412 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.